| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3045 | 2013 |
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized MF Van Delft, AH Wei, KD Mason, CJ Vandenberg, L Chen, PE Czabotar, ... Cancer cell 10 (5), 389-399, 2006 | 1458 | 2006 |
| Programmed anuclear cell death delimits platelet life span KD Mason, MR Carpinelli, JI Fletcher, JE Collinge, AA Hilton, S Ellis, ... Cell 128 (6), 1173-1186, 2007 | 1199 | 2007 |
| Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation JE Vince, WWL Wong, I Gentle, KE Lawlor, R Allam, L O'Reilly, K Mason, ... Immunity 36 (2), 215-227, 2012 | 521 | 2012 |
| Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function SM Schoenwaelder, Y Yuan, EC Josefsson, MJ White, Y Yao, KD Mason, ... Blood, The Journal of the American Society of Hematology 114 (3), 663-666, 2009 | 349 | 2009 |
| Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets SM Schoenwaelder, KE Jarman, EE Gardiner, M Hua, J Qiao, MJ White, ... Blood, The Journal of the American Society of Hematology 118 (6), 1663-1674, 2011 | 337 | 2011 |
| Mitochondrial apoptosis is dispensable for NLRP 3 inflammasome activation but non‐apoptotic caspase‐8 is required for inflammasome priming R Allam, KE Lawlor, ECW Yu, AL Mildenhall, DM Moujalled, RS Lewis, ... EMBO reports 15 (9), 982-990, 2014 | 240 | 2014 |
| Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets EC Josefsson, C James, KJ Henley, MA Debrincat, KL Rogers, ... Journal of Experimental Medicine 208 (10), 2017-2031, 2011 | 207 | 2011 |
| Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, ... The Lancet Oncology 20 (2), 216-228, 2019 | 186 | 2019 |
| In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas KD Mason, CJ Vandenberg, CL Scott, AH Wei, S Cory, DCS Huang, ... Proceedings of the National Academy of Sciences 105 (46), 17961-17966, 2008 | 175 | 2008 |
| Venetoclax plus R-or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial AD Zelenetz, G Salles, KD Mason, C Casulo, S Le Gouill, LH Sehn, H Tilly, ... Blood, The Journal of the American Society of Hematology 133 (18), 1964-1976, 2019 | 131 | 2019 |
| BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs EM Carrington, IB Vikstrom, A Light, RM Sutherland, SL Londrigan, ... Proceedings of the National Academy of Sciences 107 (24), 10967-10971, 2010 | 115 | 2010 |
| The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia KD Mason, SL Khaw, KC Rayeroux, E Chew, EF Lee, WD Fairlie, ... Leukemia 23 (11), 2034-2041, 2009 | 112 | 2009 |
| The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? KD Mason, SK Juneja, J Szer Blood reviews 20 (2), 71-82, 2006 | 82 | 2006 |
| Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis M Speir, KE Lawlor, SP Glaser, G Abraham, S Chow, A Vogrin, ... Nature microbiology 1 (3), 1-9, 2016 | 75 | 2016 |
| Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma L Coyle, NJ Morley, A Rambaldi, KD Mason, G Verhoef, CL Furness, ... Leukemia & lymphoma 61 (9), 2103-2112, 2020 | 70 | 2020 |
| Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombocytopenia V Necchi, A Balduini, P Noris, S Barozzi, P Sommi, C Di Buduo, ... Thrombosis and haemostasis 109 (02), 263-271, 2013 | 60 | 2013 |
| Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease KD Mason, A Lin, L Robb, EC Josefsson, KJ Henley, DHD Gray, BT Kile, ... Proceedings of the National Academy of Sciences 110 (7), 2599-2604, 2013 | 55 | 2013 |
| HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia G Brumatti, M Salmanidis, CH Kok, RA Bilardi, JJ Sandow, N Silke, ... Oncotarget 4 (11), 1933, 2013 | 53 | 2013 |
| Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type … Y Zhao, NA Scott, S Fynch, L Elkerbout, WWL Wong, KD Mason, ... Diabetologia 58, 140-148, 2015 | 36 | 2015 |
